# Hiromichi Ebi

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hiromichi-ebi/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,788 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 42 |
| i10-index | 77 |
| Last Known Institution | Aichi Cancer Center |
| OpenAlex ID | https://openalex.org/A5088194700 |
| ORCID iD | 0000-0003-3155-7576 |
| Works | 240 |

## Researcher papers

- [EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i> -Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib](https://scholariq.org/papers/egfr-mediated-reactivation-of-mapk-signaling-contributes-to-insensitivity-of-i/)
- [Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO–ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS](https://scholariq.org/papers/pan-asian-adapted-esmo-consensus-guidelines-for-the-management-of-patients-with/)
- [Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK](https://scholariq.org/papers/therapeutic-strategies-to-overcome-crizotinib-resistance-in-non-small-cell-lung/)
- [A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response](https://scholariq.org/papers/a-murine-lung-cancer-co-clinical-trial-identifies-genetic-modifiers-of/)
- [Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models](https://scholariq.org/papers/synthetic-lethal-interaction-of-combined-bcl-xl-and-mek-inhibition-promotes/)
- [Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92](https://scholariq.org/papers/apoptosis-induction-by-antisense-oligonucleotides-against-mir-17-5p-and-mir-20a/)
- [BIM Expression in Treatment-Naïve Cancers Predicts Responsiveness to Kinase Inhibitors](https://scholariq.org/papers/bim-expression-in-treatment-naive-cancers-predicts-responsiveness-to-kinase/)
- [PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer](https://scholariq.org/papers/pten-loss-mediates-clinical-cross-resistance-to-cdk4-6-and-pi3k-inhibitors-in/)
- [Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer](https://scholariq.org/papers/epithelial-to-mesenchymal-transition-is-a-cause-of-both-intrinsic-and-acquired/)
- [Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial](https://scholariq.org/papers/circulating-tumor-dna-guided-treatment-with-pertuzumab-plus-trastuzumab-for-her2/)
- [ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitors](https://scholariq.org/papers/araf-amplification-in-small-cell-lung-cancer-transformed-tumors-following/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)
- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [PI3K/AKT/mTOR signaling in cancer](https://scholariq.org/topics/pi3k-akt-mtor-signaling-in-cancer/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

## Researcher university

- [Aichi Cancer Center](https://scholariq.org/institutions/aichi-cancer-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.